Concord Drugs Ltd Upgraded to Hold by MarketsMOJO on Technical and Financial Improvements

Technical Trends Shift to Neutral Territory

The primary catalyst for the rating upgrade lies in the technical domain, where Concord Drugs’ trend has shifted from mildly bearish to sideways. Weekly technical indicators present a more constructive picture: the Moving Average Convergence Divergence (MACD) on a weekly basis has turned bullish, while monthly MACD remains mildly bearish, indicating a potential inflection point in momentum.

Additional technical signals support this cautious optimism. The weekly Bollinger Bands are bullish, suggesting price volatility is favouring upward movement, and the monthly Bollinger Bands are mildly bullish. The Know Sure Thing (KST) indicator is mildly bullish weekly and bullish monthly, reinforcing the view of improving momentum. However, some caution remains as daily moving averages are mildly bearish and the weekly Dow Theory assessment is mildly bearish, reflecting some residual selling pressure.

Price action has responded accordingly, with the stock closing at ₹79.11 on 23 Sep 2026, up 6.91% from the previous close of ₹74.00. The stock’s 52-week range stands between ₹61.00 and ₹92.52, indicating room for upside relative to recent highs.

Financial Performance: Exceptional Quarterly Growth

Concord Drugs’ financial trend has been a significant factor in the upgrade. The company reported outstanding results for Q1 FY26-27, with net profit surging by 825% year-on-year to ₹1.11 crore, marking the highest quarterly profit recorded. Profit Before Tax excluding other income (PBT LESS OI) grew by an impressive 862.50% to ₹1.54 crore, while net sales expanded by 53.93% to ₹20.95 crore.

This strong performance follows positive results in the preceding quarter, signalling sustained operational momentum. Over the past year, the company’s profits have risen by 162%, outpacing its stock return of 18.09%, which itself has comfortably outperformed the Sensex’s negative 8.86% return over the same period.

Despite these gains, the company’s long-term financial strength remains mixed. The average Return on Capital Employed (ROCE) stands at a modest 5.41%, reflecting limited efficiency in capital utilisation. Operating profit has grown at a subdued annual rate of 9.20% over the last five years, and the company’s ability to service debt is weak, with an average EBIT to interest ratio of just 1.76. These factors temper enthusiasm and justify a Hold rating rather than a more bullish stance.

Valuation Remains Attractive Amid Micro-Cap Status

Valuation metrics also support the revised rating. Concord Drugs is classified as a micro-cap stock, trading at a discount relative to its peers’ historical averages. The company’s ROCE of 5.2% and an Enterprise Value to Capital Employed ratio of 1.9 indicate an attractive valuation base for investors seeking value in the pharmaceuticals sector.

The company’s Price/Earnings to Growth (PEG) ratio is a notably low 0.2, suggesting that the stock is undervalued relative to its earnings growth potential. This valuation appeal is reinforced by the stock’s long-term performance, with returns of 134.82% over three years and 158.11% over five years, significantly outperforming the Sensex’s respective returns of 13.36% and 24.95%.

However, a slight concern is the reduction in promoter holding to 45.08% this quarter, which may raise questions about insider confidence and governance stability.

Quality Assessment: Mixed Signals

Concord Drugs’ overall quality rating remains moderate, reflected in its Mojo Score of 51.0 and a Mojo Grade of Hold, upgraded from Sell on 23 Sep 2026. The company’s quality metrics are influenced by its micro-cap status and the mixed financial fundamentals. While recent quarterly results demonstrate operational excellence, the longer-term growth and capital efficiency metrics remain average at best.

The company’s ability to generate returns on capital is limited, and its debt servicing capacity is weak, which constrains the quality rating. Nonetheless, the recent earnings surge and improving technical outlook provide a foundation for cautious optimism.

Market Performance and Comparative Returns

Concord Drugs has delivered market-beating returns in both the short and long term. Over the past year, the stock has appreciated by 18.09%, outperforming the Sensex’s decline of 8.86%. Over three and five years, the stock’s returns of 134.82% and 158.11% respectively dwarf the Sensex’s 13.36% and 24.95% gains, underscoring the company’s strong relative performance.

However, recent weekly returns have been slightly negative at -0.24%, compared to the Sensex’s positive 0.66%, indicating some short-term volatility. Monthly returns remain positive at 5.48%, outperforming the Sensex’s -3.50% over the same period.

These figures highlight Concord Drugs’ resilience and potential for further gains, albeit with some near-term fluctuations.

Conclusion: A Balanced Hold Recommendation

The upgrade of Concord Drugs Ltd’s investment rating to Hold reflects a balanced assessment of its improving technical indicators, exceptional recent financial results, and attractive valuation metrics against a backdrop of mixed long-term fundamentals. The company’s strong quarterly growth and market-beating returns provide a compelling case for investors to maintain exposure, while caution is warranted due to average capital efficiency and weak debt servicing ability.

Investors should monitor the company’s promoter holding trends and longer-term financial stability alongside technical developments to gauge future rating changes. For now, the Hold rating signals a prudent stance, recognising both the upside potential and inherent risks in this micro-cap pharmaceutical stock.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today